Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
|Slideshows|February 12, 2018
Lifestyle, Personality, and Metabolic Changes in the Elderly
Author(s)Mark L. Fuerst
Three new studies on genetic risk factors and lifestyle; the transition from cognitive health to Alzheimer disease; and metabolic syndrome in depressed older adults.
Advertisement
Advertisement
Related to this article
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
5